Fig. 1 · Structure

Documents & Downloads

SCH 900776 (MK-8776)

Cat. No. A11167 CAS 891494-63-6

Chk1 inhibitor

SCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities. It specifically binds to and inhibits Chk1, which may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases to undergo DNA repair prior to entry into mitosis; tumor cells may thus be sensitized to the DNA-damaging effects of ionizing radiation and alkylating chemotherapeutic agents.

In Stock

Publications for SCH 900776

5 publications citing this product

  1. Hong Yang, .et al. , Research Square, 2022, May 9th
  2. Motofumi Suzuki, .et al. , Int J Radiat Oncol Biol Phys, 2021, May 25;S0360-3016(21)00361-8 PMID: 34112559
  3. Min Wu, .et al. , Haematologica, 2019, 104 PMID: 30975911
  4. Permata TBM, .et al. , Oncogene, 2019, Feb 12 PMID: 30755733
  5. Hiro Sato, .et al. , Nat Commun, 2017, 8: 1751 PMID: 29170499

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SCH 900776 (MK-8776) is used as a CHK1-pathway inhibitor in cancer research. In a cellular pathway study, MK8776 attenuated DNA damage-induced PD-L1 expression, supporting a role for CHK1 signaling in this response. This experiment does not establish a biochemical IC50 or kinase-selectivity profile. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Chk1 IC50 3 nM
Chk2 IC50 1500 nM
CDK2 IC50 160 nM

SCH 900776 (MK-8776) Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of SCH 900776 (MK-8776) from 2 published references.

SCH 900776 (MK-8776) In Vitro Studies

MK8776 (50 nM, added 30 minutes before 10 Gy irradiation) reduced PD-L1 mRNA in U2OS cells and cell-surface PD-L1 in U2OS, H1299 and DU145 cells at 48 hours. These expression measurements do not demonstrate an immune or therapeutic response. [1]

MK8776 attenuates radiation-induced PD-L1 expression

Cell-based study · U2OS osteosarcoma cells; U2OS, H1299 lung cancer and DU145 prostate cancer cells for surface PD-L1 [1]

At 50 nM, MK8776 reduced radiation-induced PD-L1 mRNA in U2OS and surface PD-L1 in three cancer cell lines. The protein blot provides qualitative supporting evidence. These expression endpoints support involvement of CHK1 signaling; they do not establish biochemical selectivity, immune-cell function or antitumor efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PD-L1 mRNA in U2OS after 10 Gy, with or without MK8776Relative mRNA level Reduced with MK8776 versus irradiation alone; mean with s.d. of three independent experiments; Figure 2 has no numerical bar labels; no values digitized[1]
Cell-surface PD-L1 in U2OS, H1299 and DU145 after 10 Gy, with or without MK8776Mean fluorescence intensity Reduced with MK8776 versus irradiation alone in all three models; mean with s.d. of three independent experiments; Figure 2 has no numerical bar labels; no values digitized[1]

Literature-Reported Treatment Conditions

Treatment concentration
MK8776 50 nM
Exposure duration
Added 30 min before irradiation; endpoints at 48 h after irradiation
Method
Cell-culture treatment with or without 10 Gy X-rays
Vehicle
DMSO control labeled in Figure 2f–g; final solvent percentage not specified in the reviewed methods
Co-treatment
10 Gy X-ray irradiation; nonirradiated DMSO and irradiated DMSO controls; UCN-01 tested as a separate CHK1-inhibitor comparator
Reported limits
No lot number, salt specification or analytical stereochemical validation in reviewed drug methods; Figure 2 has no numerical bar labels. No MK8776 IC50 measured in this experiment.
Methods and source locations

Compound reported in the paper: MK8776 (SCH 900776); Compound label in the paper: Chk1i (MK)

Evidence for the named research compound in these cancer-cell conditions; no validation of the current Adooq lot or of clinical activity.

Figure 2e–g and caption; Results: PD-L1 upregulation requires ATM/ATR/Chk1 activity after DSBs; Methods: Cell culture, irradiation and drug treatment; Quantification of mRNA expression levels by real-time PCR; Surface flow cytometry analysis of PD-L1

PD-L1 mRNA in U2OS after 10 Gy, with or without MK8776: Real-time PCR, 48 h after irradiation; normalized to GAPDH. — Figure 2f and caption; Methods: Quantification of mRNA expression levels by real-time PCR

Cell-surface PD-L1 in U2OS, H1299 and DU145 after 10 Gy, with or without MK8776: Flow cytometry with PD-L1-APC; propidium-iodide-negative cells analyzed at 48 h. — Figure 2g and caption; Methods: Surface flow cytometry analysis of PD-L1

SCH 900776 (MK-8776) In Vivo Studies

In NSG mice bearing DOCK2 knockdown MV4;11 leukemia cells, MK8776 (10 mg/kg, intraperitoneal) plus cytarabine (50 mg/kg) for three days modestly prolonged median survival to 85 days, compared with 81 days for cytarabine and 70 days for MK8776 alone. No significant benefit was observed in the control-shRNA model. Survival was measured from transplantation; treatment began on day 49 in knockdown recipients and day 12 in control recipients. [2]

Cytarabine plus MK8776 in control and DOCK2 knockdown AML xenografts

Animal study · Female NSG (NOD/Shi-scid/IL-2Rg-null) mice, 6–8 weeks, bearing human FLT3-ITD-positive MV4;11 cells expressing control shRNA (C) or shRNA against DOCK2 (KD) [2]

Combination benefit depended on cell background. In the KD model, cytarabine plus MK8776 modestly prolonged survival versus either single agent and reduced marrow blast burden. In the C model, no significant survival or marrow-blast difference was observed among the tested treatments. Treatment began on different post-transplant days in the two strata, precluding a simple drug-only interpretation of between-stratum survival differences.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Median survival of DOCK2 KD MV4;11 recipients, measured from transplantationMedian survival (days) Vehicle 68 (n=5); MK8776 70 (n=5); ara-C 81 (n=9); ara-C+MK8776 85 (n=9)[2]
Median survival of control-shRNA MV4;11 recipients, measured from transplantationMedian survival (days) Vehicle 19 (n=9); MK8776 20 (n=5); ara-C 20 (n=5); ara-C+MK8776 19 (n=5); no significant treatment differences reported[2]
Bone-marrow leukemic blast percentage 7 days after treatment startHuman-cell engraftment (%) Combination significantly reduced marrow blast percentage versus either single agent in KD recipients; no significant treatment differences in C recipients. Exact plotted means not tabulated.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
KD — VehicleVehicle and both single agents within the same cell-genotype stratumMedian survival 68 days from transplantation[2]
KD — MK8776
MK8776 10 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 70 days from transplantation[2]
KD — Cytarabine
Cytarabine 50 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 81 days from transplantation[2]
KD — Cytarabine + MK8776
Cytarabine 50 mg/kg + MK8776 10 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 85 days from transplantation; modest significant prolongation versus either single agent[2]
C — VehicleVehicle and both single agents within the same cell-genotype stratumMedian survival 19 days from transplantation; no significant treatment differences reported within the C stratum[2]
C — MK8776
MK8776 10 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 20 days from transplantation; no significant treatment differences reported within the C stratum[2]
C — Cytarabine
Cytarabine 50 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 20 days from transplantation; no significant treatment differences reported within the C stratum[2]
C — Cytarabine + MK8776
Cytarabine 50 mg/kg + MK8776 10 mg/kg
Vehicle and both single agents within the same cell-genotype stratumMedian survival 19 days from transplantation; no significant treatment differences reported within the C stratum[2]
KD — Vehicle
Model: NSG mice with DOCK2 knockdown MV4;11 cells; survival n=5
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 49 after transplantation
Vehicle: Vehicle composition not explicitly assigned for this control arm
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
KD — MK8776
Model: NSG mice with DOCK2 knockdown MV4;11 cells; survival n=5
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 49 after transplantation
Vehicle: 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
KD — Cytarabine
Model: NSG mice with DOCK2 knockdown MV4;11 cells; survival n=9
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 49 after transplantation
Vehicle: PBS
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
KD — Cytarabine + MK8776
Model: NSG mice with DOCK2 knockdown MV4;11 cells; survival n=9
Frequency: Once daily for 3 consecutive days; MK8776 30 min after cytarabine
Treatment course: Treatment started day 49 after transplantation
Vehicle: MK8776 in 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin; cytarabine in PBS
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
C — Vehicle
Model: NSG mice with control-shRNA MV4;11 cells; survival n=9
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 12 after transplantation
Vehicle: Vehicle composition not explicitly assigned for this control arm
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
C — MK8776
Model: NSG mice with control-shRNA MV4;11 cells; survival n=5
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 12 after transplantation
Vehicle: 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
C — Cytarabine
Model: NSG mice with control-shRNA MV4;11 cells; survival n=5
Frequency: Once daily for 3 consecutive days
Treatment course: Treatment started day 12 after transplantation
Vehicle: PBS
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
C — Cytarabine + MK8776
Model: NSG mice with control-shRNA MV4;11 cells; survival n=5
Frequency: Once daily for 3 consecutive days; MK8776 30 min after cytarabine
Treatment course: Treatment started day 12 after transplantation
Vehicle: MK8776 in 45% (w/v) (2-hydroxypropyl)-β-cyclodextrin; cytarabine in PBS
Reported limits: No exact pairwise P value or confidence interval for median survival reported in Figure 5; survival cohort distinct from marrow cohort.
Methods and source locations

Compound reported in the paper: MK8776 (SCH 900776); Compound label in the paper: MK8776

A condition-dependent preclinical combination result in an immunodeficient leukemia model, including an inactive control-cell stratum.

Figure 5A–B and caption (including printed median-survival table and survival-cohort legend); Methods: Mouse transplantation experiments and Statistics; Results: DOCK2 knockdown enhances the efficacy of ara-C treatment in a mouse xenograft model; Supplement Reagents, PDF p. 2

Median survival of DOCK2 KD MV4;11 recipients, measured from transplantation: Survival monitoring; log-rank testing described in Statistics. Figure 5A reports a significant combination advantage over either single agent; exact P values not supplied. — Figure 5A printed median-survival table and cohort legend

Median survival of control-shRNA MV4;11 recipients, measured from transplantation: Survival monitoring; values transcribed from printed table, not estimated from curves. — Figure 5A printed median-survival table and cohort legend; corresponding Results paragraph

Bone-marrow leukemic blast percentage 7 days after treatment start: Flow-cytometric human/mouse CD45 assessment; 3–5 mice per treatment group sacrificed for marrow analysis; source reports mean ± SEM. — Figure 5B and caption; corresponding Results paragraph; Methods: Mouse transplantation experiments

KD — Vehicle · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

KD — MK8776 · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

KD — Cytarabine · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

KD — Cytarabine + MK8776 · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

C — Vehicle · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

C — MK8776 · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

C — Cytarabine · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

C — Cytarabine + MK8776 · Figure 5A, printed median-survival table and cohort legend; Methods: Mouse transplantation experiments; Supplement Reagents, PDF p. 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 891494-63-6
Applications Chk1 inhibitor
Formula C15H18BrN7
Molecular Weight 376.25
Synonyms MK-8776
SMILES
NC1=C(Br)C([C@H]2CNCCC2)=NC3=C(C4=CN(C)N=C4)C=NN13

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
4% DMSO+30% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SCH 900776 (MK-8776) Research References

  1. [1] Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells Nature communications (2017). PMID: 29170499 DOI: 10.1038/s41467-017-01883-9 Source material
  2. [2] Wu M, Li L, Hamaker M, et al. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways Haematologica (2019). PMID: 30975911 DOI: 10.3324/haematol.2018.208843 Source material

Publications

5 publications citing this product

  1. Hong Yang, .et al. , Research Square, 2022, May 9th
  2. Motofumi Suzuki, .et al. , Int J Radiat Oncol Biol Phys, 2021, May 25;S0360-3016(21)00361-8 PMID: 34112559
  3. Min Wu, .et al. , Haematologica, 2019, 104 PMID: 30975911
  4. Permata TBM, .et al. , Oncogene, 2019, Feb 12 PMID: 30755733
  5. Hiro Sato, .et al. , Nat Commun, 2017, 8: 1751 PMID: 29170499

Added to your cart

View Cart Checkout
Loading...